Gamma-linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial
β Scribed by Robert B. Zurier; Ronald G. Rossetti; Eric W. Jacobson; Deborah M. Demarco; Nancy Y. Liu; Joseph E. Temming; Bernadette M. White; Michael Laposata
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 971 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective Spleen tyrosine kinase (Syk) has been identified as an important modulator of immune signaling in B cells and cells bearing FcΞ³βactivating receptors. R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro
## Abstract ## Objective To determine whether patients with undifferentiated arthritis (UA; inflammatory, nontraumatic arthritis that cannot be diagnosed using current classification criteria) benefit from treatment with methotrexate (MTX). ## Methods The PRObable rheumatoid arthritis: Methotrex